- Home
- BXC vs RAPT Comparison
BXC vs RAPT Comparison
Compare BXC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- RAPT
- Stock Information
- Founded
- BXC 2004
- RAPT 2015
- Country
- BXC United States
- RAPT United States
- Employees
- BXC N/A
- RAPT N/A
- Industry
- BXC Wholesale Distributors
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- BXC Consumer Discretionary
- RAPT Health Care
- Exchange
- BXC Nasdaq
- RAPT Nasdaq
- Market Cap
- BXC 443.9M
- RAPT 498.4M
- IPO Year
- BXC 2004
- RAPT 2019
- Fundamental
- Price
- BXC $63.77
- RAPT $33.50
- Analyst Decision
- BXC Strong Buy
- RAPT Strong Buy
- Analyst Count
- BXC 3
- RAPT 9
- Target Price
- BXC $88.67
- RAPT $57.00
- AVG Volume (30 Days)
- BXC 108.2K
- RAPT 407.3K
- Earning Date
- BXC 11-04-2025
- RAPT 11-06-2025
- Dividend Yield
- BXC N/A
- RAPT N/A
- EPS Growth
- BXC N/A
- RAPT N/A
- EPS
- BXC 1.71
- RAPT N/A
- Revenue
- BXC $2,948,840,000.00
- RAPT N/A
- Revenue This Year
- BXC $1.54
- RAPT N/A
- Revenue Next Year
- BXC $4.30
- RAPT N/A
- P/E Ratio
- BXC $36.31
- RAPT N/A
- Revenue Growth
- BXC N/A
- RAPT N/A
- 52 Week Low
- BXC $52.71
- RAPT $5.67
- 52 Week High
- BXC $130.06
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- BXC 52.09
- RAPT 68.63
- Support Level
- BXC $53.71
- RAPT $26.50
- Resistance Level
- BXC $60.42
- RAPT $29.29
- Average True Range (ATR)
- BXC 3.02
- RAPT 1.77
- MACD
- BXC 0.94
- RAPT 0.12
- Stochastic Oscillator
- BXC 89.20
- RAPT 83.60
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.